Paris, 10 October 2014 - NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced the installation today of its new international scientific committee in New York.
In order to strengthen its scientific base and increase the visibility in the scientific community of its innovative technology in the treatment of autoimmune diseases, Neovacs has decided to be supported in its development by an international Scientific Committee which will meet in New York on a regular basis. This committee is composed of leading world experts in the activity fields of Neovacs, immune therapy, chronical inflammatory and autoimmune diseases.
This Committee will be chaired by Professor Jacques Banchereau, Jackson Laboratory for Genomic Medicine, Farmington, CT, USA and be composed of:
Prof. David G.Brooks, Phd
UCLA, Los Angeles, CA
Prof. Jean-Frédéric Colombel, MD
Helmsley Inflammatory Bowel Disease center
Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital, New York, NY
Prof. Michael Ehrenstein, MB BS, PhD, FRCP
University College London, London, UK
Prof. Paul Emery, MA MD FRCP
University of Leeds, Leeds, UK
Prof. Bernard Lauwerys, MD, PhD
Cliniques Universitaire St Luc & Université Catholique de Louvain, Brussels, Belgium
Prof. Miriam Merad, MD, PhD
Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital, New York, NY
Prof. Virginia Pascual, MD
Baylor Institute for Immunology Research, Dallas, TX
Their mission will consist of advising the company in its therapeutic targets on the base of their scientific and clinical experience in immunotherapy and in the choices to be taken within the preclinical and clinical developments of its products.
Miguel Sieler, CEO of Neovacs declared: “We are very happy and very proud to be able to count in the future on the advice of this new International Scientific Committee. Its location in New York is an important step in our strategy to develop our activity in the USA”.
About Neovacs
Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by six patent families that run until at least 2023) Neovacs is focusing its development efforts on two active immunotherapies: TNF-Kinoid is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, whereas IFNa-Kinoid is being developed for the indication of lupus. Neovacs is also conducting preclinical works on IFNa-Kinoid in certain chronic viral infections, VEGF-Kinoid in Age-related Macular Degeneration (AMD) and solid tumors, and IL-4-Kinoid for the treatment of allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
For more information on Neovacs, visit www.neovacs.fr
Press & Financial Communication France - Publicis
Stéphanie Tabouis
+33 (0) 1 44 82 46 35
stéphanie.tabouis@consultants.publicis.fr
Aubane de Gélis
+33 (0) 1 44 82 46 38
aubane.de-gelis@consultants.publicis.fr
Help employers find you! Check out all the jobs and post your resume.
